Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation
| dc.contributor.author | Kurt, Ada Sera | |
| dc.contributor.author | Ruiz, Paula | |
| dc.contributor.author | Landmann, Emmanuelle | |
| dc.contributor.author | Elgosbi, Marwa | |
| dc.contributor.author | Fung, Tsz Kan | |
| dc.contributor.author | Kodela, Elisavet | |
| dc.contributor.author | Londoño, María Carlota | |
| dc.contributor.author | Marin Correa, Diana | |
| dc.contributor.author | Perpiñán, Elena | |
| dc.contributor.author | Lombardi, Giovanna | |
| dc.contributor.author | Safinia, Niloufar | |
| dc.contributor.author | Martinez Llordella, Marc | |
| dc.contributor.author | Sanchez Fueyo, Alberto | |
| dc.date.accessioned | 2026-09-04T11:00:04Z | |
| dc.date.available | 2026-09-04T11:00:04Z | |
| dc.date.issued | 2024-09-19 | |
| dc.date.updated | 2026-08-21T11:55:36Z | |
| dc.description.abstract | Conferring alloantigen-specificity to ex vivo expanded CD4+CD25+FOXP3 regulatory T cells (Tregs) increases their capacity to counteract effector alloimmune responses following adoptive transfer into transplant recipients. Three strategies are currently undergoing clinical development, which involve the following: (1) expanding Tregs in the presence of donor B cells (donor alloantigen-reactive [DAR] Tregs); (2) culturing Tregs with donor cells in the presence of costimulation blockade (CSB-Tregs); and (3) transducing Tregs with an human leukocyte antigen A2-specific chimeric antigen receptor (CAR-Tregs). Our goal in this study was to assess the relative potency of each of these manufactured Treg products both in vitro and in vivo. When compared with polyclonal Tregs, all 3 manufacturing strategies increased the precursor frequency of alloreactive Tregs, and this was proportional to the overall in vitro immunosuppressive properties of the cell products. Accordingly, CARTregs, which contained the highest frequency of donor-reactive Tregs, exhibited the strongest suppressive effects on a cell-per-cell basis. Similarly, in an in vivo mouse model of graft-vs-host disease, infusion of CAR-Tregs conferred a significantly longer recipient survival than any other Treg product. Our results highlighting the alloantigen-reactivity and associated immunosuppressive properties of different manufactured Treg products have implications for the mechanistic interpretation of currently ongoing clinical trials in transplantation. | |
| dc.format.extent | 10 | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idimarina | 9457108 | |
| dc.identifier.issn | 1600-6143 | |
| dc.identifier.pmid | 39299674 | |
| dc.identifier.uri | https://hdl.handle.net/2445/231281 | |
| dc.language.iso | English | |
| dc.publisher | Elsevier Inc. | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.ajt.2024.09.009 | |
| dc.relation.ispartof | American Journal of Transplantation, 2025, vol. 25, num.1, p. 38-47 | |
| dc.relation.uri | https://doi.org/10.1016/j.ajt.2024.09.009 | |
| dc.rights | cc by (c) Kurt, Ada Sera et al., 2024 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | |
| dc.subject.classification | Cèl·lules T | |
| dc.subject.classification | Immunologia de la trasplantació | |
| dc.subject.classification | Empelts de teixits | |
| dc.subject.other | T cells | |
| dc.subject.other | Transplantation immunology | |
| dc.subject.other | Tissue transplantation | |
| dc.title | Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- Conferring alloantigen specificity to regulatory T cells....pdf
- Mida:
- 1.54 MB
- Format:
- Adobe Portable Document Format